24/7 Market News Snapshot 10 September, 2024 – Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

September 10, 2024

DENVER, Colo., 10 September, 2024 (247marketnews.com) – (NASDAQ:CRVS) are discussed in this article.
Corvus Pharmaceuticals, Inc. has demonstrated strong market activity, opening at $4.10 and currently trading at $4.635, reflecting a notable increase of 13.88% from the previous session’s closing price of $4.07. The heightened trading volume of 578.56K shares indicates a robust interest in the stock, suggesting a bullish sentiment among investors. Analysts have identified potential resistance levels near $4.70 and support around the opening price, indicating possible entry points for cautious investors who evaluate overall market conditions alongside the company’s fundamentals.

In conjunction with its market performance, Corvus Pharmaceuticals has announced the launch of a pivotal Phase 3 clinical trial for soquelitinib, an investigational drug aimed at treating relapsed peripheral T-cell lymphoma (PTCL). This randomized, controlled study seeks to compare the efficacy and safety of soquelitinib against standard chemotherapy. As a first-in-class interleukin-2-inducible T cell kinase (ITK) inhibitor, soquelitinib holds promise in transforming treatment protocols not only for cancer but also for autoimmune diseases.

Currently, patients suffering from relapsed PTCL lack fully approved treatment options, making this clinical trial particularly significant. Dr. Richard A. Miller, co-founder and CEO of Corvus, emphasized the trial’s importance as a beacon of hope for patients facing this challenging condition. The study aims to enroll approximately 150 patients who have experienced treatment failure after one to three prior lines of therapy. Participants will receive either a 200mg dose of soquelitinib twice daily or standard chemotherapy, with progression-free survival as the primary endpoint.

Earlier clinical trials have indicated that soquelitinib is well-tolerated and exhibits a durable anti-tumor activity profile, particularly in advanced cases where other treatments have proven ineffective. With the increasing incidence of PTCL and a lack of recent therapeutic advancements, this trial signifies a critical milestone for both patients and the oncology field.

Related news for (CRVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.